A5059545333- Cervical Cancer and HPV Research
- Hepatitis B Virus Studies
- Genital Health and Disease
- Global Cancer Incidence and Screening
- Esophageal Cancer Research and Treatment
- Molecular Biology Techniques and Applications
- Head and Neck Cancer Studies
- Reproductive tract infections research
- Endometrial and Cervical Cancer Treatments
- Cancer-related molecular mechanisms research
- Tracheal and airway disorders
- Traumatic Brain Injury and Neurovascular Disturbances
- Esophageal and GI Pathology
- Public Health Policies and Education
- Viral-associated cancers and disorders
- Vaccine Coverage and Hesitancy
- Neurosurgical Procedures and Complications
- Lung Cancer Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Seaweed-derived Bioactive Compounds
- Colorectal Cancer Screening and Detection
- Ear Surgery and Otitis Media
- Facial Trauma and Fracture Management
- Cerebrospinal fluid and hydrocephalus
- Cancer Risks and Factors
Merck & Co., Inc., Rahway, NJ, USA (United States)
2021-2025
McGill University
2011-2024
Decision Sciences (United States)
2024
Division of Cancer Epidemiology and Genetics
2015-2023
National Cancer Institute
2015-2023
United States Military Academy
2020-2021
National Institutes of Health
2017-2020
Genocea (United States)
2019
Bristol-Myers Squibb (Germany)
2019
Roche (Switzerland)
2019
Human papillomavirus-positive oropharynx cancer incidence has increased rapidly in cohorts of US white men born during the 1930s to 1950s. It is unknown how trajectory epidemic may be changing United States.Using registry information, we investigated whether increases have continued into recent birth and forecasted future burden across age, sex, race/ethnicity subgroups. Log-linear Joinpoint regression age-period-cohort models were used evaluate trends 1992 2015 projections through...
Currently, 2 vaccines exist that prevent infection by the genotypes of human papillomavirus (HPV) responsible for approximately 70% cervical cancer cases worldwide. Although vaccination is expected to reduce prevalence these HPV types, there concern about effect this could have on distribution other oncogenic types. According basic ecological principles, if competition exists between ≥2 different types niche occupation during natural infection, elimination 1 type may lead an increase in...
Cancer of the oropharynx has attracted considerable attention in recent years given: (1) an increasing incidence selected populations over past three decades; (2) discovery human papillomavirus (HPV) infection as driver increase, opposed to traditional risk factors such tobacco (smoking and chewing) alcohol; (3) promise new prevention treatment strategies. As a result developments, International Agency for Research on (IARC) US National Institute (NCI), convened fourth Seminar meeting...
Long-term survivors of pediatric and young adult (PAYA) cancers have a high incidence subsequent neoplasms, but few risk factors other than cancer treatment been identified. We aimed to describe the burden human papillomavirus (HPV)-associated malignancies among PAYA assess whether HPV infections might be reasonable area future etiologic research on in this population. used longitudinal data from 9 population-based registries Surveillance, Epidemiology, End Results program collected between...
Since the early 1950s, Papanicolaou (“Pap”) cytology screening has dramatically reduced cervical cancer mortality in most high-income settings. Currently, human papillomavirus (hpv) vaccination greatest potential to reduce global burden of and precancerous lesions. However, as prevalence lesions declines, maintaining primary test settings with established programs might become less efficient. A reduction performance (sensitivity, specificity, positive predictive value) would lead an increase...
Current HPV vaccines do not protect against all oncogenic types. Following vaccination, type replacement may occur, especially if different types competitively interact during natural infection. Because of their common route transmission, it is difficult to assess interactions in observational studies. Our aim was evaluate the setting vaccine randomized controlled trials (RCTs).Data were pooled from Costa Rica Vaccine Trial (CVT; NCT00128661) and PATRICIA trial (NCT001226810)-two...
We assessed the incidence and risk factors for first detection redetection with same human papillomavirus (HPV) genotype, prevalence of cytological lesions during HPV redetections.
Carrageenan demonstrated potent anti-HPV (human papillomavirus) activity in vitro and animal models. The Carrageenan-gel Against Transmission of Cervical Human papillomavirus trial's interim analysis (n = 277) a 36% protective effect carrageenan against incident HPV infections. Herein, we report the final results.In this exploratory phase IIB randomised, placebo-controlled trial, recruited healthy women aged ≥18 years primarily from health service clinics at two Canadian Universities...
The AS04-adjuvanted HPV16/18 (AS04-HPV16/18) vaccine provides excellent protection against targeted human papillomavirus (HPV) types and a variable degree of cross-protection others, including 6/11/31/33/45. High efficacy any cervical intraepithelial neoplasia grade 3 or greater (CIN3+; >90%) suggests that lower levels may exist for wide range oncogenic HPV types, which is difficult to quantify in individual trials. Pooling individual-level data from two randomized controlled trials, we...
Post-marketing surveillance studies provide conflicting evidence about whether Guillain-Barre syndrome occurs more frequently following quadrivalent human papillomavirus (HPV4) vaccination. We aimed to assess is reported HPV4 vaccination than other vaccinations among females and males aged 9 26 y in the United States. used adverse event reports received by States Vaccine Adverse Event Reporting System (VAERS) between January 1, 2010 December 31, 2012 estimate overall, age-, sex-specific...
Abstract It has been hypothesized that, following a reduction in human papillomavirus (HPV) vaccine–targeted genotypes, an increase prevalence of other HPV types may occur due to reduced competition during natural infection. Any apparent postvaccination must be distinguished from diagnostic artifacts consequent consensus PCR assays failing detect present low copy numbers coinfected specimens (under the assumption that with drop vaccine-preventable there increased detection previously...
The incidence of oropharynx cancers has increased substantially in the United States. However, risk stratification tools for identification high-risk individuals do not exist. In this study, an individualized prediction model was developed and validated US population.A synthetic, population-based case-control study conducted. Oropharynx cancer cases diagnosed at Ohio State University (n = 241) were propensity-weighted to represent occurring annually States during 2009-2014 12,656). Controls...
Abstract In Denmark, vaccination against human papillomavirus (HPV) has been implemented in the children's program (January 2009) and multiple catch‐up cohorts (October 2008 girls 13‐15 years August 2012 women up to 27 years). present study we estimate incidence of cervical intraepithelial neoplasia grade 3 (CIN3), adenocarcinoma situ (AIS), squamous cell carcinoma (SCC) (AC) during 2000‐2019. All cases CIN3 AIS were identified from nationwide Pathology Data Bank, while SCC AC Danish Cancer...
Abstract Background International data on anogenital HPV infection incidence among men are limited. Methods Incidence of incident-persistent (IP) infections was evaluated 295 who have sex with (MSM) and 1576 heterosexual (HM) aged 16–27 years in the placebo arm a global, multicenter 4-valent (4v) vaccine trial. We estimated IP (penile/scrotal, perineal/perianal, anal) for 4vHPV 9-valent (9v) types cumulative over 36 months. Results per 100 person-years (95% CI) HM 9vHPV 4.1 (3.5–4.9) 6.8...
PURPOSE The incidence of oral tongue cancers has increased since the 1980s among US men and women for unknown reasons. We investigated associations inflammatory conditions with risk tongue, other cavity, oropharynx elderly individuals (age 65 years or older). METHODS conducted a case-control study (2,534 cancers, 6,832 cavity 9,373 oropharyngeal 200,000 controls) within SEER-Medicare data set (1992-2013). Medicare records were used to identify patients clinically diagnosed (glossitis, benign...